Research programme: fixed combinations for cardiovascular indications - HanAll BiopharmaAlternative Names: HL013 (hypertension/hyperlipidemia functional combination) - HanAll Biopharma; HL037; HL053; HL162
Latest Information Update: 08 Feb 2011
At a glance
- Originator HanAll Biopharma
- Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hyperlipidaemia; Hypertension
Most Recent Events
- 08 Feb 2011 This programme is ongoing in South Korea